Registry to assess light therapy for dry age-related macular degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The EUROLIGHT study is a multi-center registry that aims to gather real-world data on the safety and effectiveness of the Valeda® photobiomodulation (PBM) system for treating dry age-related macular degeneration (AMD). Participants will receive a series of non-invasive light treatments over a period of three to four weeks, with the possibility of additional treatments every few months. Visual outcomes will be measured using standard assessments such as visual acuity and imaging techniques like OCT and Fundus Autofluorescence. The study will include both retrospective and prospective data collection from up to 20 sites across Europe.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator;
2. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study;
3. Informed of the nature of this study and has provided written, informed consent; (participants enrolled retrospectively will need to be contacted and sign an informed consent form prior to their data being used).

Exclusion Criteria:

* US Sites Only: Center-involving geographic atrophy;
* Neovascular maculopathy;
* Use of any photosensitizing agent (e.g. topicals, injectables) activated by the Valeda Light Deliver System within 30 days prior to treatment without consulting participant's physician;
* Known photosensitivity to yellow light, red light, or near infrared radiation (NIR), or has a history of light activated central nervous system disorders (e.g. epilepsy, migraine);
* In the opinion of the Investigator, is unlikely to comply with the study protocol or has a history or current evidence of any condition that, in the opinion of the investigator, might interfere with the participant's involvement in the trial, or is not in the best interest of the participant.

Where it's running

• Valley Retina Institute
  McAllen, Texas, United States Recruiting
• Retina Vitreous Associates Medical Group
  Beverly Hills, California, United States Not yet recruiting
• Cincinnati Eye Institute
  Cincinnati, Ohio, United States Not yet recruiting
• Carolina Eyecare Physicians
  Charleston, South Carolina, United States Not yet recruiting
• Pacific Northwest Retina
  Silverdale, Washington, United States Not yet recruiting
• Institutt for Oyehelse
  Oslo, Norway Active not recruiting

Study contacts

• Study coordinator: Alcon Call Center
• Email: alcon.medinfo@alcon.com
• Phone: 1-888-451-3937

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• OCU410 for Geographic Atrophy due to Dry AMD: treatment to help the eye

  A Phase 3 trial tests whether a single subretinal injection of OCU410 can help people 55 and older with geographic atrophy from dry AMD.

  Recruiting Phase 3 Ocugen · Phoenix, Arizona and 2 other locations · NCT07770828

• PathFinder 1.0 detects retinal abnormalities on macular OCT scans

  This study tests PathFinder 1.0's ability to find retinal issues on macular OCT scans in adults.

  Recruiting at 5 sites Carl Zeiss Meditec-Dublin CoCe · Tucson, Arizona and 5 other locations · NCT07680244

• Subretinal CPCB-RPE1 implant for advanced dry AMD with geographic atrophy

  This trial will try a surgical CPCB-RPE1 implant in one eye to see if it is safe and helps people aged 55–90 with advanced dry AMD and geographic atrophy that involves the fovea.

  Recruiting at 5 sites Phase 2 Regenerative Patch Technologies, LLC · Huntington Beach, California and 4 other locations · NCT06557460

• Treatment for dry age-related macular degeneration using umbilical cord blood plasma

  This study is testing if injections of umbilical cord blood plasma can help older adults with dry age-related macular degeneration slow down or improve their vision.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Rome · NCT06536062

• Treatment for dry age-related macular degeneration using umbilical cord blood platelet-rich plasma injections

  This study is testing if injections of umbilical cord blood platelets can help older adults with dry age-related macular degeneration keep their vision from getting worse.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT05706896

• Transplanting stem cells to treat dry age-related macular degeneration

  This study is testing a new stem cell treatment for people with dry age-related macular degeneration to see if it is safe and well-tolerated.

  Recruiting at 3 sites Phase 1/2 Luxa Biotechnology, LLC · Beverly Hills, California and 2 other locations · NCT04627428

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.